New proteasome inhibitors in the treatment of multiple myeloma

The treatment of patients with relapsed and/or refractory multiple myeloma has improved considerably in the last 15 years, after the introduction of proteasome inhibitors and immunomodulatory drugs. The first clinical trials with new proteasome inhibitors have produced exciting results, particularly...

Descripción completa

Detalles Bibliográficos
Autores principales: Hungria, Vania Tietsche de Moraes, Crusoé, Edvan de Queiroz, Bittencourt, Rosane Isabel, Maiolino, Angelo, Magalhães, Roberto José Pessoa, Sobrinho, Jairo do Nascimento, Pinto, Jorge Vaz, Fortes, Ricardo Coutinho, Moreira, Eloisa de Sá, Tanaka, Paula Yurie
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Sociedade Brasileira de Hematologia e Hemoterapia 2019
Materias:
Review Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6371737/
https://www.ncbi.nlm.nih.gov/pubmed/30793108
http://dx.doi.org/10.1016/j.htct.2018.07.003

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6371737/
https://www.ncbi.nlm.nih.gov/pubmed/30793108
http://dx.doi.org/10.1016/j.htct.2018.07.003

Ejemplares similares